Xenon Pharmaceuticals
XENE
79 hedge funds and large institutions have $351M invested in Xenon Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 11 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
13% more funds holding
Funds holding: 70 → 79 (+9)
12% more capital invested
Capital invested by funds: $314M → $351M (+$36.6M)
0.68% more ownership
Funds ownership: 79.26% → 79.95% (+0.68%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$10.7M |
| 2 |
O
OrbiMed
New York
|
+$10.6M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$10.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.78M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$4.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$22.4M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$17M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.5M |
| 4 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$2.11M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.85M |
XENE Hedge Fund Activity: Q2 2020 in Review
79 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2020, worth a combined $351M — up 12% from $314M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new XENE positions and 11 closed out — a net gain of 9 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was BVF Inc, adding an estimated $10.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $22.4M sold.
- 79 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2020, up from 70 in Q1 2020.
- Funds reported $351M of Xenon Pharmaceuticals stock for Q2 2020, up 12% quarter-over-quarter.
- 20 funds opened new Xenon Pharmaceuticals positions in Q2 2020 and 11 closed out, a net change of +9 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2020 was BVF Inc, an estimated $10.7M added.
- The largest Xenon Pharmaceuticals seller in Q2 2020 was Consonance Capital Management, an estimated $22.4M sold.
Based on aggregated 13F filings for Q2 2020.